Acne volgaris. infectios of the skin and subcutaneos tissue
Conditions
Interventions
Intervention 1: Intervention group 1: 34 patients will be treated with tablets omeprazole 20 mg (one a day) with a solution of erythromycin topical 4%Pak Daru (twice daily). Intervention 2: Control gr
Treatment - Drugs
Intervention group 1: 34 patients will be treated with tablets omeprazole 20 mg (one a day) with a solution of erythromycin topical 4%Pak Daru (twice daily)
Control group:34 atients will be treated with Doxycycline 100 mg capsule daily with 4% Erythromycine solution Pak twice daily.
Sponsors
Vice chancellor for research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 44 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria included a diagnosis of acne = Score EGGS 3; insensitivity to macrolides and proton pump inhibitors: lack of active liver or kidney disease; avoiding the use of warfarin; phenytoin; diazepam:Older than 12 years;17 to 40 inflammatory lesions (papules, nodules, pustules);20 to 100; closed or open comedones .Exclusion criteria:patients with criteria for pregnancy and lactation; allergic reactions to medications; exacerbation;Astringent and topical abrasive consumption one week before the start of treatment;topical treatment of acne products; including soaps; antimicrobial consumption and comedogenic products for 2 weeks before treatment;The use of topical retinoids; retinol and systemic acne treatments one month before treatment; the use of systemic retinoids 6 months befor of treatment;oligomenorrhea;Hirsutism;taking OCP; systemic antibiotics for at least 1 month before treatment;fulminant;body acne alone.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical remission and response to treatment of inflammatory lesions. Timepoint: Patients at weeks 2, 4, 6, 8, 10 and 12 will be evaluated. Method of measurement: the improvement of clinical acne, severity and response to treatment of inflammatory lesions (80% and above = good - between 50 and 79% = middle = 20% and down 49% = less = no response) to be discussed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: Weeks 2, 4, 6, 8, 10 and 12. Method of measurement: History and clinical observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanieh Sharifian
Skin disease & Leishmaniasis Research Center
Outcome results
None listed